AXIAL Logo 2021MAR05.png
Axial Therapeutics CEO A. Stewart Campbell to Present at Microbiome Connect: USA 2022
01 nov. 2022 08h00 HE | Axial Therapeutics
WOBURN, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
AXIAL Logo 2021MAR05.png
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
11 oct. 2022 08h00 HE | Axial Therapeutics
- Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism; data anticipated in 2023 - - Team also supporting additional microbiome-based small molecule...
AXIAL Logo 2021MAR05.png
Axial Therapeutics to Present at BioJapan Conference
06 oct. 2022 08h00 HE | Axial Therapeutics
WOBURN, Mass., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...
AXIAL Logo 2021MAR05.png
Axial Therapeutics CEO, A. Stewart Campbell, to Participate at the Longwood Healthcare Leaders Fall Webconference
13 sept. 2022 08h00 HE | Axial Therapeutics
WOBURN, Mass., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Axial Therapeutics Inc., a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for...